This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) shares have rallied 62% over the past six months due to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake of its first marketed product, Empaveli, has further bolstered the stock value.
IMGNPositive Net Change APLSPositive Net Change AKROPositive Net Change
biotechnology medical
Corning (GLW) Launches Viridian Vials for Sustainable Future
by Zacks Equity Research
Corning's (GLW) Viridian Vials is likely to revolutionize pharmaceutical glass-packaging with significant environmental benefits while meeting the industry's growing demand for efficient production.
AKAMPositive Net Change GLWPositive Net Change IDCCPositive Net Change
biotechnology communications tech-stocks
After Golden Cross, Lear (LEA)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LEAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery
by Zacks Equity Research
Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.
NVDAPositive Net Change AKROPositive Net Change RXRXNo Net Change
biotechnology medical
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
by Zacks Equity Research
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
IMGNPositive Net Change ARDSNo Net Change AKROPositive Net Change
biotechnology medical
Greenbrier Companies (GBX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GBXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
by Zacks Equity Research
Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.
BIIBPositive Net Change BMYPositive Net Change NVAXNegative Net Change PRTANegative Net Change CRBUPositive Net Change
biotechnology pharmaceuticals
Is Now the Right Time to Embrace Biotech ETFs?
by Yashwardhan Jain
Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
AMGNPositive Net Change GILDPositive Net Change VRTXNegative Net Change IBBPositive Net Change XBIPositive Net Change BBHPositive Net Change ARKGPositive Net Change
biotechnology etfs
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
NVSPositive Net Change INCYNegative Net Change LGNDPositive Net Change ABBVPositive Net Change
biotechnology pharmaceuticals
ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study
by Zacks Equity Research
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.
RHHBYPositive Net Change ADCTPositive Net Change AKROPositive Net Change
biotechnology medical
Helen of Troy (HELE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HELENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.
BMYPositive Net Change IMGNPositive Net Change AKROPositive Net Change
biotechnology medical
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study
by Zacks Equity Research
Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.
MRKNegative Net Change INFIPositive Net Change MEIPPositive Net Change AKROPositive Net Change
biotechnology medical
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY
by Zacks Equity Research
Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.
BIIBPositive Net Change BMYPositive Net Change LGNDPositive Net Change PRTANegative Net Change
biotechnology biotechs pharmaceuticals
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
NVSPositive Net Change LGNDPositive Net Change ABBVPositive Net Change BLCONegative Net Change
biotechnology pharmaceuticals
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
NVSPositive Net Change JAZZPositive Net Change AXSMPositive Net Change AKROPositive Net Change
biotechnology medical
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
by Zacks Equity Research
Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies are part of the Zacks Screen of the Week article.
USAPPositive Net Change ARLOPositive Net Change PHATPositive Net Change
biotechnology computers
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechnology medical
JetBlue Airways (JBLU) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
JBLUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Jul 7, 2023
by Zacks Equity Research
Companies in The News Are: JBLU, AAL, F, MRNA, GENI.
FPositive Net Change JBLUPositive Net Change MRNANegative Net Change AALPositive Net Change GENIPositive Net Change
airlines auto-tires-trucks biotechnology internet-content
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
by Zacks Equity Research
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
PFENegative Net Change ALKSNegative Net Change LGNDPositive Net Change CRBUPositive Net Change
biotechnology biotechs
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
BMRNNegative Net Change LLYPositive Net Change MRNANegative Net Change AMRXPositive Net Change
biotechnology biotechs
The Zacks Analyst Blog Highlights Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group
by Zacks Equity Research
Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group are part of the Zacks top Analyst Blog.
AAPLPositive Net Change VZNegative Net Change AMGNPositive Net Change SCHWPositive Net Change CINegative Net Change
biotechnology communications computers finance insurance
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology pharmaceuticals
Kite Realty Group (KRG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KRGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines